Sia Daneshmand, MD, on what comes next after EV/pembro

At the recent BCAN Think Tank meeting, Sia Daneshmand, MD, delivered a talk titled, “Evolving Care Strategies After EV-Pembro in Bladder Cancer.”¹ Daneshmand recently sat down with Urology Times® to detail the key takeaways from this discussion.

Daneshmand is professor of urology, the director of clinical research, and the urologic oncology fellowship director at the University of Southern California in Los Angeles.

Daneshmand specifically highlights data that was presented by Comron Hassanzadeh, MD, MPH, exploring the potential of combining EV/checkpoint inhibitors with radiotherapy, suggesting it might improve outcomes, especially for oligoprogressive disease. Daneshmand also emphasized the importance of monitoring bladder disease through routine cystoscopies and local therapies like radiation or surgery for residual muscle-invasive disease.

He noted, "There are patients who respond with their distant disease with EV/pembro, and yet have either progression or continue have to have disease in the bladder. I think it's important not to forget that and have a close relationship with the urologist and make sure you are doing endoscopy of the bladder every few months at least, to make sure there's not progressive disease in the bladder."

REFERENCE

1. Daneshmand S. What Comes Next: Evolving Care Strategies After EV-Pembro in Bladder Cancer. Presented at: BCAN Think Tank. Washington DC. July 30-August 1, 2025.